Photo by nci from unsplash
The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. Click to show full abstract
The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals.
Keywords:
compaction cardiomyopathy;
non compaction;
use sacubitril;
sacubitril valsartan
Journal Title: ESC Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESC Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!